SOBI exercises opt-in right to take over final Alprolix development and commercialization

16 July 2015

Nordic biotech firm Swedish Orphan Biovitrum (STO: SOBI) has decided to exercise its opt-in right to take over the final development and commercialization of Alprolix (rFIXFc) for Europe, North Africa, Russia and certain Middle East markets.

The drug is a recombinant factor IX Fc fusion protein product candidate for the treatment of hemophilia B. SOBI will make a $10 million payment to Biogen (Nasdaq: BIIB), which will be held in escrow pending the European Union regulatory approval of Alprolix.

Geoffrey McDonough, chief executive at SOBI, said: "This is an important milestone for Sobi and the result of a strong collaboration between Sobi and Biogen. We are looking forward to the possibility of making this innovative treatment available for people with hemophilia B upon approval in our territory, increasing treatment choices and advancing patient care for the hemophilia community."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK